Associate Professor of Pharmacy Practice, School of Pharmacy, UNE
Psychiatry and Substance Use Disorder Faculty, Maine Medical Center
Stephanie Nichols, PharmD, BCPS, BCPP, FCCP is an Associate Professor of Pharmacy Practice at the University of New England School of Pharmacy, Adjunct Clinical Assistant Professor of Psychiatry at the Tufts University School of Medicine, and faculty for the Maine Medical Center (MMC) Psychiatric Physician Residency Program and core faculty for the MMC/Veteran Affairs Addiction Medicine Felowship. She graduated from the University at Buffalo with her Doctor of Pharmacy degree and completed an Inpatient Pharmacy Practice Residency at Maine Medical Center. Nichols is dual-board certified as a Pharmacotherapy Specialist (BCPS) and a Psychiatric Pharmacist (BCPP) and is a fellow of the American College of Clinical Pharmacy (FCCP).
1. Drugs and Disease VIII: Immunomodulation, Pain, and Opioid Use Disorder (PHAR 583)
2. Drugs and Disease XI: Neurology and Substance Use Disorders (PHAR 584)
3. Advanced Pharmacy Practice Experiences: Inpatient/Acute Care (6 week long clinical rotations at MMC with a psych/SUD focus) (PHAR 443)
At MMC, Nichols and her students are involved in providing direct patient care to patients with mental illness, responding to psychopharmacotherapy consults, educating patients, healthcare professional students, residents, fellows, and life-long learners, and participating in population health endeavors including co-development of ordersets, policies, and procedures
Nichols is extremely passionate about interprofessional education and care and about reducing stigma around mental illness and SUDs. Research interests for Nichols include the following.
1. Developing programs and evaluating their ability to optomize the treatment of people with SUDs, prevent development of SUD in patients with mental illness and/or trauma, and prevent and mitigate medication-related medical problems and adverse effects.
2) Epidemiology of people with SUDs and related morbidity and mortality, medical and nonmedical controlled substance use, and psychotropic polypharmacy
3) Prospective investigational research about psychotropic medications and/or the interface between medical and psychiatric co-morbidities and associated medications, including drug-drug interactions, drug-disease interactions, and drud induced diseases or disorders.
She has co-authored publications in Pharmacotherapy, Mental Health Clinican, Psychosomatics, Pain, PeerJ, PLOS One, American Journal of Health System Pharmacy, Journal of the American College of Clinical Pharmacy, Journal of Maine Medical Center, Pharmacology, Journal of Addiction Medicine, and Journal of Drug and Alcohol Dependence.
Nichols serves as a Senior Editor for the College of Psychiatric and Neurologic Pharmacists Board Certified Psychiatric Pharmacist Preparation and Recertification Book, an expert consultant for the SAMHSA Opioid Response Network, a member of the Maine Opioid Response Clinical Advisory Committee and Maine Prescription Monitoring Program Committee, a member of the Board of Directors for Co-Collaborative Serving Maine, a member of the Lunder Dineen Time to Ask Advisory Committee, and as a member of the Institute for Clinical and Economic Review's New England Comparative Effectiveness Public Advisory Committee. She includes her clinical students in these meetings and activities whenever possible.
Adult mental health
Core Faculty, MMC/VA ACGME-accredited Addiction Medicine Fellowship
Instructor, MMC ACGME-accredited Psychiatry Residency Program
Board Certified Psychiatric Pharmacist (BCPP)
Certificate, Effective Teaching Practices (Course 50-hours over 25 weeks), Association of College and University Educators, 2017 - 2018
Certificate, Public Health in the Opioid Crisis Leadership Development Program, Maine Medical Association and Maine Quality Counts, 2017 - 2019
Certificate, Class of XIV, Hanley Health Leadership Development Program, 2020 - 2021
Selected publications follow.
1. Peckham AM, Ball J, Colvard MD, Dadiomov D, Hill LG, Nichols SD, Tallian K, Ventricelli DJ, Tran TH. Leveraging pharmacists to maintain and extend buprenorphine supply for opioid use disorder amid COVID-19 pandemic. Am J Health-Syst Pharm. 2021;78:xxx-xxx. PMID 33411894
2. Loskutova NY, Lutgen C, Smail C, Staton EW, Nichols SD, Pinckney RG. Stimulant Prescribing Error Assessment Rubric Development. J Patient Saf. 2020 Sep 8. doi: 10.1097/PTS.0000000000000775. PMID 32925567
3. Abrams B, Murray K, Mahoney K, Raymond K, McWilliams S, Nichols S, Mahmoudi E, Mayes L, Fernandez-Bustamante A, Mitchell J, Meguid R, Zanotti G, Bartels K. Post-discharge pain management after thoracic surgery – a patient centered approach. Ann Thorac Surg. 2020 Jun 1;S0003-4975(20)30780-3. PMID 32497643
4. Badowski ME, Wright E, Bainbridge J, Michienzi S, Nichols SD, Turner K, Wicke C, Awad J, Thompkins A, Martin R. ACCP White Paper: Implementation and evaluation of comprehensive medication management in telehealth practices. J Am Coll Clin Pharm. 2020;3:520–531. Link
5. Leung JG, Cusimano JM, Kemp M, Gannon JM, Milgrom O, Valcourt SC, Stoklosa JB, Olsufka W, Vickery PB, Nichols SD, Crouse EL, Paxos C, Johnson EK, Palmer BA. Addressing clozapine under-prescribing and barriers to initiation: A psychiatrist, advanced practice provider, and trainee survey. Int Clin Psychopharmacol. 2019;34(5):247-256. PMID 31107831
6. Wolfrum LA, Nordmeyer AS, Racine CW, Nichols SD. Loperamide-associated opioid use disorder and proposal of an alternative treatment with buprenorphine. J of Addict Med. 2019;13(3): 245-47. PMID 30379781
7. Piper BJ, Ogden CL, Simoyan OM, Chung DY, Caggiano JF, Nichols SD, McCall KL. Trends in use of prescription stimulants in the United States and Territories, 2006 to 2016. PLoS ONE. 2018;13(11):e0206100. PMID 30485268
8. Piper BJ, Shaw DT, Simoyan OM, McCall KM, Nichols SD. Trends in medical use of opioids in the United States: 2006 – 2016. Am J Preventative Med. 2018;54(5):652-660. PMID 29551331
9. Piper BJ, Desrociers C, McCall KL, Nichols SD. Illicit and prescription drug misuse as reported to the Maine Diversion Alert Program. Forensic Sci Int. 2018;285:65-71. PMID 29453006
10. Holt T, McCall KL, Cattabriga G, Tu C, Smalley EK, Nichols SD. Using controlled substance receipt patterns to predict prescription overdose death. Pharmacology. 2017;14;101(3- 4):140-147. PMID 29248915
11. Piper BJ, DeKeuster RM, Beals ML, Cobb C, Burchman CA, Perkinson L, Lynn ST, Nichols SD, Abess AT. Substitution of medical cannabis for pharmaceutical agents for pain, anxiety, and sleep. Journal of Psychopharmacology. 2017;31(5):569–575. PMID 28372506
12. Piper BJ, Desrosiers CE, Fisher HC, McCall KL, Nichols SD. A new tool to tackle the opioid epidemic: description, utility and results from the Maine Diversion Alert Program. Pharmacotherapy. 2017;37(7):791-798. PMID 28543168
13. Nichols SD, Bulman M, Tisher A, Campbell J. A case of possible iatrogenic ketamine-induced mania in a patient being treated for post-operative pain. Psychosomatics. 2016;57(5):543-46. PMID 27614210
14. Nichols SD, Bishop J. Is the evidence compelling for using ketamine to treat resistant depression? Current Psychiatry. 2016;15(5):48-51. Link
15. McCall K, Nichols SD, Holt C, Ochs L, Cattabriga G, Tu C. Prescription Monitoring Program trends among individuals arrested in Maine for trafficking prescription drugs in 2014. Pharmacotherapy. 2016;36(6):585-9. PMID 27087386
Invited plenary presentation
1. Buprenorphine and Methadone in Transitions of Care, College of Psychiatric and Neurologic Pharmacists, Dallas, Texas, 2020 (emergency conversion to virtual teaching)
2. The Maine Pharmacist Provider Collaboration Task Force: Affecting Change in ME, APhA PharmTALK, Seattle, Washington, 2019